Researchers led by Paranos and colleagues report a jumbo bacteriophage with activity against metallo‑β‑lactamase (MBL)‑producing Pseudomonas aeruginosa, a pathogen frequently resistant to carbapenems and other beta‑lactams. The study demonstrates the phage’s lytic capacity against clinical MBL strains in vitro and characterizes genomic features that may underlie host range and stability. The work highlights bacteriophage therapy as a potential adjunctive or salvage option for multidrug‑resistant Gram‑negative infections, pending in vivo efficacy and safety testing.